Aug 9 |
Kiora Pharmaceuticals GAAP EPS of -$0.53 beats by $0.33
|
Aug 9 |
Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies
|
Jul 30 |
Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies
|
Jul 10 |
Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation
|
Jul 1 |
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors
|
Jun 25 |
Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board
|
Jun 18 |
Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now?
|
Jun 11 |
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) stock most popular amongst retail investors who own 39%, while hedge funds hold 31%
|
May 29 |
Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024
|
May 20 |
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences
|